Antibiotics have been a cornerstone of modern medicine for nearly a century — but a world where they no longer work reliably is closer than most people realize. Bacteria are becoming progressively more resistant to standard treatment, a trend accelerated by the COVID-19 pandemic and the tripledemic that followed.
The scale of the problem
In 2019, an estimated 1.27 million people died directly from drug-resistant infections, and 4.95 million deaths involved drug-resistant infections in some way. So-called "superbugs" — organisms with resistance to every antibiotic on the shelf — are no longer hypothetical.
How COVID-19 made it worse
From 2019 to 2020, hospitalization-associated infections grew by 15%. Roughly 80% of patients hospitalized with COVID received antibiotics — most prescribed empirically for suspected bacterial co-infection that was later not confirmed. The result: enormous selective pressure for resistance, in exactly the populations most likely to spread it.
What reverses the trend
Antibiotic stewardship
Use antibiotics only when truly indicated, and choose the narrowest agent that will work. Stewardship programs have been shown to reduce resistance pressure without compromising patient outcomes.
Better diagnostics
Empirical broad-spectrum prescribing is largely a workaround for slow, narrow diagnostics. Next-generation sequencing identifies pathogens and the resistance genes they carry from a single sample — enabling targeted therapy from day one rather than the second or third antibiotic round, with AI-powered analysis increasingly catching novel resistance variants traditional databases miss.
Sustained investment
The pipeline of new antibiotics is thin. Public and private investment — alongside microbiome-based therapeutics, phage therapy, and vaccines — needs to expand to keep pace with bacterial evolution.
Where Biotia fits
BIOTIA-DX and BIOTIA-ID translate sequencing data into clinically actionable pathogen and resistance reports — closing the diagnostic gap that fuels empirical prescribing. Better data at the point of care is one of the most concrete things we can do to slow AMR.
Frequently asked questions
What causes antimicrobial resistance?
AMR is driven primarily by overuse and misuse of antibiotics — both empirical prescribing without diagnostic confirmation and broad-spectrum use when narrower agents would work. Each exposure selects for resistant strains.
How did COVID-19 affect AMR?
Hospital-associated infections rose 15% in the first year of the pandemic, and 80% of hospitalized COVID patients received antibiotics — most for suspected, not confirmed, bacterial co-infection. That created enormous selective pressure for resistance.
What can be done?
Three things, working together: stewardship (only prescribe antibiotics when needed), diagnostics (sequencing-based pathogen and resistance identification so treatment is targeted), and continued investment in new antibiotics and microbiome therapeutics.